FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 718 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Why Have Thyroid Cancer Diagnoses Spiked for US Women? September 28, 2021 Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... July 4, 2024 FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend... July 9, 2019 Load more HOT NEWS Why consistent and funded cancer policies are key to improving cancer... New Treatment Helps Survivors Regain Sensation After Breast Cancer New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and... Protective HPV Vaccine-Induced Antibody Titres Can Be Detected Up To 12...
